# OnCo record esophageal (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/esophageal/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "esophageal" ;
  schema:name "Oesophageal cancer"@en ;
  schema:alternateName "ESCA"@en, "TCGA-ESCA"@en, "oesophageal carcinoma (TCGA ESCA cohort)"@en ;
  schema:description "Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."@en ;
  schema:url <https://onco.cc/cancers/esophageal/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Esophageal_cancer> ;
  owl:sameAs <http://www.wikidata.org/entity/Q372701> ;
  schema:citation <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1433>, <https://www.esmo.org/guidelines/esmo-clinical-practice-guidelines-gastrointestinal-cancers/>, <https://www.cancer.gov/types/esophageal/hp/esophageal-treatment-pdq> ;
  onco:tag "gi", "spike" ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/bispecific-adc/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/gastric-endoscopic-screening/>, <https://onco.cc/technologies/endoscopic-resection/>, <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/technologies/brachytherapy/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/her3/>, <https://onco.cc/targets/her2/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/ctla4/>, <https://onco.cc/targets/cldn18-2/>, <https://onco.cc/targets/vegf/> ;
  onco:companies <https://onco.cc/companies/nanjing-leads-biolabs/>, <https://onco.cc/companies/neonc-technologies/>, <https://onco.cc/companies/ap-biosciences/>, <https://onco.cc/companies/merck/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/beone/>, <https://onco.cc/companies/systimmune/>, <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/daiichi-sankyo/>, <https://onco.cc/companies/jazz/> ;
  onco:institutions <https://onco.cc/institutions/jiangsu-cancer-hospital/>, <https://onco.cc/institutions/nki/>, <https://onco.cc/institutions/sysucc/>, <https://onco.cc/institutions/ncc-japan/>, <https://onco.cc/institutions/cams-cancer-hospital/> ;
  onco:pathways <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/ras-mapk/> ;
  onco:terms <https://onco.cc/terms/escc-vs-eac/>, <https://onco.cc/terms/barretts-esophagus/>, <https://onco.cc/terms/siewert-classification/>, <https://onco.cc/terms/clinical-complete-response/>, <https://onco.cc/terms/cps/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/pcr/>, <https://onco.cc/terms/endoscopic-resection-term/>, <https://onco.cc/terms/flot-term/> ;
  onco:trials <https://onco.cc/trials/rationale-302/>, <https://onco.cc/trials/symbiotic-gi-16/>, <https://onco.cc/trials/nct07463573/>, <https://onco.cc/trials/nct06194734/>, <https://onco.cc/trials/nct04415853/>, <https://onco.cc/trials/nct06356311/>, <https://onco.cc/trials/nct06022861/>, <https://onco.cc/trials/nct07217704/>, <https://onco.cc/trials/nct07431281/>, <https://onco.cc/trials/nct06644781/>, <https://onco.cc/trials/nct07554456/>, <https://onco.cc/trials/nct04550260/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-spotlight-lancet-2023/>, <https://onco.cc/key-papers/paper-alcohol-cancer-burden-lancet-oncol-2021/> ;
  onco:journals <https://onco.cc/journals/esophagus-journal/> ;
  onco:pipeline <https://onco.cc/drugs/izalontamab-brengitecan/>, <https://onco.cc/drugs/pf-08634404/>, <https://onco.cc/drugs/hs-20093/>, <https://onco.cc/drugs/qlc5508/>, <https://onco.cc/drugs/kc1036/>, <https://onco.cc/drugs/hlx43/>, <https://onco.cc/drugs/gotistobart/>, <https://onco.cc/drugs/lerotinib/>, <https://onco.cc/drugs/mcla-129/>, <https://onco.cc/drugs/tqb6411/>, <https://onco.cc/drugs/hmbd-001/>, <https://onco.cc/drugs/azd5863/>, <https://onco.cc/trials/panku-esophagus01/>, <https://onco.cc/trials/sano/>, <https://onco.cc/ideas/idea-organ-preservation-esophageal/>, <https://onco.cc/ideas/idea-non-endoscopic-barretts-screening/>, <https://onco.cc/trials/herizon-gea-01/>, <https://onco.cc/drugs/zanidatamab/>, <https://onco.cc/drugs/tislelizumab/>, <https://onco.cc/trials/clarity-gastric01/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/fapi-pet/>, <https://onco.cc/pairings/cross-then-nivolumab/>, <https://onco.cc/trials/checkmate-648/> ;
  onco:standardOfCare <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/izalontamab-brengitecan/>, <https://onco.cc/technologies/endoscopic-resection/>, <https://onco.cc/terms/barretts-esophagus/>, <https://onco.cc/ideas/idea-non-endoscopic-barretts-screening/>, <https://onco.cc/technologies/endoscopic-resection/>, <https://onco.cc/trials/cross/>, <https://onco.cc/trials/checkmate-577/>, <https://onco.cc/drugs/flot/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/pairings/cross-then-nivolumab/>, <https://onco.cc/trials/sano/>, <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/terms/clinical-complete-response/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/platinum/>, <https://onco.cc/trials/keynote-590/>, <https://onco.cc/trials/checkmate-648/>, <https://onco.cc/trials/rationale-306/>, <https://onco.cc/trials/escort-1st/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/tislelizumab/>, <https://onco.cc/drugs/camrelizumab/>, <https://onco.cc/trials/keynote-590/>, <https://onco.cc/trials/checkmate-649/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/zanidatamab/>, <https://onco.cc/drugs/zolbetuximab/>, <https://onco.cc/trials/panku-esophagus01/>, <https://onco.cc/drugs/izalontamab-brengitecan/>, <https://onco.cc/trials/destiny-gastric04/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/ramucirumab/>, <https://onco.cc/trials/clarity-gastric01/>, <https://onco.cc/technologies/brachytherapy/>, <https://onco.cc/technologies/imrt-igrt/> .